The Danish drugmaker Novo Nordisk has officially launched its weight loss pill, Wegovy, in the United States as of March 15, 2024. The medication, which is...
Eli Lilly is positioning itself for sustained growth in the pharmaceutical sector by capitalizing on its leading role in diabetes and obesity treatments. The company is...
China has officially added drugs from three major pharmaceutical companies—Eli Lilly, Pfizer, and Johnson & Johnson—to its inaugural innovative drug catalog for private insurance. This list...
Eli Lilly, Pfizer, and Johnson & Johnson have been included in China’s first innovative drug catalog for private insurance. This significant development features 19 high-cost medications...
U.S. stock markets experienced a substantial rally during the week ending November 24, 2023, buoyed by strong performances from major healthcare companies, including Sanofi, Eli Lilly,...
U.S. stock markets experienced a notable rally during the trading week ending November 24, 2023, buoyed by strong performances from major healthcare companies such as Sanofi,...
Novo Nordisk has announced significant price reductions for its obesity treatments, Wegovy and Ozempic, in an effort to compete more effectively against rival Eli Lilly, which...
Novo Nordisk has announced a significant price reduction for its weight-loss injection, Wegovy, by up to 37% in India. This strategic decision comes as the Danish...
Shares in Novo Nordisk dropped by as much as 3 percent on Friday following a pricing agreement between the Danish pharmaceutical company and its U.S. competitor...
South Korea’s Celltrion has finalized the acquisition of Eli Lilly‘s production facility located in Branchburg, New Jersey, for $330 million. This transaction, confirmed through a regulatory...
